Table 4.
Summary of Schwann cell conversion
| Species | Cell source | Reprogramming factors | Target cell type (Efficiency) | Duration (Days) | In vitro disease modeling | In vivo transplantation | References |
|---|---|---|---|---|---|---|---|
| Human | Fibroblasts | SOX10 | SOX10＋ NCSCs (∼2%) | >14 days |
Not shown (CMT1A pathogenesis, as shown in Mukherjee-Clavin et al., 2019) | Chick embryos | Kim et al., 2014 |
| MPZ＋ or S100β＋ SCs (Not shown) | ∼35 days | ||||||
| Human | Fibroblasts | Chemical condition | GFAP＋ or S100β＋ SCs (Not shown) | >27 days | Not shown | Not shown | Thoma et al., 2014 |
| Human | Fibroblasts | SOX10, EGR2 | S100β＋ SCs (∼43%) | >10 days | Not shown | The sciatic nerve of nude and NOD/SCID mice | Sowa et al., 2017 |
| Human (mouse) | Fibroblasts | SOX10, EGR2 | S100β＋ SCs (>5%) |
>14 days |
Not shown | Not shown | Mazzara et al., 2017 |
| MPZ＋ SCs (Not available) | >21 days | ||||||
| Human | Fibroblasts | Chemical condition | GFAP＋ or S100β＋ SCs (Not shown) | >9 days | Not shown | The sciatic nerve injury rat model | Kiada et al., 2019 |
| Human | Fibroblasts | OCT4, SOX2, KLF4, MYCL1, and LIN28 and p53 shRNA | SOX10＋ SCPs (∼97%) |
>18 days |
Not shown | The sciatic nerve injury mouse model | Kim et al., 2020 |
| S100β＋ or NGFR＋ SCs (>95%) | >25 days |